Continuous monitoring changed the question and not the assay
HbA1c integrates roughly three months of glycaemia with the most recent weeks weighted most heavily. Almost every misreading of it is a misreading of that weighting.
Trial design
Page 32 of 32 of this archive, newest first.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The glycated haemoglobin assay, and the eight conditions that break it
The assay is not the problem. The interpretation of a lagging integral as a current measurement is the problem.
From the floor in Xianning: 4 posters, one theme
Reported from the sessions, and from the two hours afterwards.
SURMOUNT-OSA extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A design note on withdrawal trials, and why the run-in matters
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.